These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 24200492)

  • 1. Expression profile of osteoprotegerin, RANK and RANKL genes in the femoral head of patients with avascular necrosis.
    Samara S; Dailiana Z; Chassanidis C; Koromila T; Papatheodorou L; Malizos KN; Kollia P
    Exp Mol Pathol; 2014 Feb; 96(1):9-14. PubMed ID: 24200492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of osteoprotegerin, RNAK and RANKL genes in femoral head avascular necrosis and related signaling pathway.
    Miao Q; Hao S; Li H; Sun F; Wang X
    Int J Clin Exp Pathol; 2015; 8(9):10460-7. PubMed ID: 26617755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Osteoprotegerin mRNA/receptor activator of NF-kappaB ligand mRNA expressions in bone tissues of glucocorticoid-induced osteonecrosis of the femoral head].
    Wang J; Wang K; Shi Z; Zhang M
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2008 Oct; 22(10):1161-4. PubMed ID: 18979868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Wenyangbushen formula on the expression of VEGF, OPG, RANK and RANKL in rabbits with steroid-induced femoral head avascular necrosis.
    Song HM; Wei YC; Li N; Wu B; Xie N; Zhang KM; Wang SZ; Wang HM
    Mol Med Rep; 2015 Dec; 12(6):8155-61. PubMed ID: 26496816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Osteoprotegerin and receptor activator of nuclear factor kappa B ligand mRNAs expression in BMSCs of glucocorticoid-induced necrosis of the femoral head patients].
    Wang J; Gao H; Wang K; Li W; Shi Z; Zhang M
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2009 Jul; 23(7):777-80. PubMed ID: 19662974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of osteoprotegerin, RANK and RANKL on bone destruction and collapse in avascular necrosis femoral head.
    Xiong MY; Liu LQ; Liu SQ; Liu ZH; Gao HF
    Am J Transl Res; 2016; 8(7):3133-40. PubMed ID: 27508034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of Epimedium extract on osteoprotegerin and RANKL mRNA expressions in glucocorticoid-induced femoral head necrosis in rats].
    Wang JZ; Gao HY; Wang KZ; Zhou RX; Li XD; Guo J; Lv HC
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Oct; 31(10):1714-7. PubMed ID: 22027774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
    Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
    Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
    Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
    J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-145 Mediates Steroid-Induced Necrosis of the Femoral Head by Targeting the OPG/RANK/RANKL Signaling Pathway.
    Zhao JJ; Wu ZF; Wang L; Feng DH; Cheng L
    PLoS One; 2016; 11(7):e0159805. PubMed ID: 27459539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
    Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
    Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of icariin on the regulation of the OPG-RANKL-RANK system are mediated through the MAPK pathways in IL-1β-stimulated human SW1353 chondrosarcoma cells.
    Wang Z; Ding L; Zhang S; Jiang T; Yang Y; Li R
    Int J Mol Med; 2014 Dec; 34(6):1720-6. PubMed ID: 25270538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-34a alleviates steroid-induced avascular necrosis of femoral head by targeting Tgif2 through OPG/RANK/RANKL signaling pathway.
    Peng WX; Ye C; Dong WT; Yang LL; Wang CQ; Wei ZA; Wu JH; Li Q; Deng J; Zhang J
    Exp Biol Med (Maywood); 2017 Jun; 242(12):1234-1243. PubMed ID: 28454497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
    Liu W; Zhang X
    Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice.
    Cao J; Venton L; Sakata T; Halloran BP
    J Bone Miner Res; 2003 Feb; 18(2):270-7. PubMed ID: 12568404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expressions of RANK, RANKL, and osteoprotegerin in male rats at different ages].
    Zhou XW; Liu YC; Jian XC; Lei YH; Wu Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Sep; 31(9):1539-42. PubMed ID: 21945761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
    Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM
    Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Genomic approaches to bone and joint diseases. Mutations of RANK, OPG and RANKL genes found in humans].
    Kobayashi Y; Takahashi N
    Clin Calcium; 2008 Feb; 18(2):202-9. PubMed ID: 18245890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
    Schubert A; Schulz H; Emons G; Gründker C
    Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.
    Yonou H; Horiguchi Y; Ohno Y; Namiki K; Yoshioka K; Ohori M; Hatano T; Tachibana M
    Prostate; 2007 Jun; 67(8):840-8. PubMed ID: 17394194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.